Cancer Medicines, Research & Diagnostics

Cancer care links established oncology drug franchises with the research tools and diagnostic platforms used to develop treatments and guide patient decisions. The basket pairs diversified commercial businesses with more focused cancer-testing companies rather than betting on a single experimental therapy. Ahead of upcoming healthcare earnings, the focus is evidence of durable treatment demand and diagnostic adoption; reimbursement pressure and clinical setbacks remain key risks. Launch basket (equal weight): MRK, ABBV, AMGN, LLY, TMO, NTRA, GH, TEM, REGN Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.